Broadcast Date: 
  • Time: 

Targeted resequencing of both DNA and RNA allows researchers to focus on genes of interest to cost-effectively interrogate genetic variations in their samples such as SNVs, CNVs, and gene fusions.

During this webinar we will describe and present data from a novel and flexible NGS target enrichment method that utilizes Single Primer Enrichment Technology (SPET). The approach can be used for a range of NGS-based analyses including identification of gene fusion events in RNA samples, targeted gene expression analysis, variant detection, and CNV analysis in DNA samples. The simple one-day protocol can generate sequence-ready libraries with as little as 10 ng DNA or total RNA from a broad range of samples. The enrichment assay is fully customizable to the user’s requirements.

We will also discuss data generated with a 344 cancer gene panel using gDNA from both fresh and FFPE samples and a gene fusion panel designed to 500 genes implicated in fusion events (as defined in the Wellcome Trust COSMIC database, ChimerDB 2.0 and TCGA) with RNA from both primary and cultured cell lines.

Who Should Attend

  • Cancer researchers interested in gene fusions
  • R&D scientists using NGS as a tool for sequence analysis
  • Researchers selectively targeting the genome to discover biomarkers for mutations, variant detection, CNV and gene fusions
  • Clinical research and development scientists developing NGS-based diagnostic and prognostic tests based on genomic biomarkers
  • Scientists performing NGS targeted gene expression analysis

You Will Learn

  • How the novel Single Primer Enrichment Technology (SPET) differs from existing target enrichment methods and demonstrates superior sequencing performance metrics in aligned reads, bases on target, uniform coverage and lower drop-out rates
  • How Single Primer Enrichment Technology (SPET) is employed with a panel of 500 cancer genes as a rapid, cost-effective screening tool for discovery of novel fusion events and detection of known fusion events
  • How NuGEN’s cancer panel design of 344 cancer-related genes demonstrates sensitive variant detection from genomic DNA derived from fresh and formalin-fixed paraffin embedded tissue (FFPE)

Produced with support from:

Sponsor Logo


Steven Kain, Ph.D.
NuGEN Technologies

Jonathan Scolnick, Ph.D.,
NuGEN Technologies